KP 136

Subscribe to Selected New Research on KP 136

4 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: RN given refers to parent cpd

Also Known As:

8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one; KP 136, potassium salt; KP 136, sodium salt; KP-136; 2H-1-Benzopyran-2-one, 8-(hexyloxy)-3-(1H-tetrazol-5-yl)-

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Tetrazoles: 5

KP 136: 4

2-Ring Heterocyclic Compounds

Benzopyrans: 5

Chromones: 17

KP 136: 4

Related Diseases

1.	Hypersensitivity (Allergy) 03/01/1990 - "The pharmacological properties of KP-136, an inhibitor of type I allergy, were studied in rat paw models" 03/01/1990 - "In four allergic responses, three of the immediate type and one delayed type, KP-136 (p.o.) produced potent inhibitions on the mast cell-mediated type I allergy (ID30: 1.0 mg/kg) and the neutrophil-infiltrated passive Arthus reaction (ID30: 1.6 mg/kg)" 04/01/1987 - "In four rat cutaneous reactions produced by three allergic reactions and compound 48/80, KP-136 was remarkably effective on two homologous PCA induced by IgE and IgGa" Get all the results and reference details, order at left...
2.	Hemolysis 12/01/1988 - "KP-136 also inhibited A23187- and heat-induced degranulation and heat-induced hemolysis" 03/01/1990 - "Although KP-136 was a weak inhibitor of carrageenin-induced paw edema, prostaglandin synthesis and complement-mediated hemolysis, the compound inhibited the release of lysosomal enzymes such as lysozyme and beta-glucuronidase in the passive Arthus reaction, suggesting the blockage of inflammatory mediator release for its mode of action." Get all the results and reference details, order at left...
3.	Inflammation 03/01/1990 - "In addition, KP-136 (10 mg/kg, 50 mg/kg, p.o.) inhibited the injury of bone tissues in rat adjuvant arthritis, confirming that it was effective on the allergic inflammation with tissue injury" Get all the results and reference details, order at left...
4.	Edema 03/01/1990 - "Effect of KP-136 on allergic paw edema in the rat]" 03/01/1990 - "Although KP-136 was a weak inhibitor of carrageenin-induced paw edema, prostaglandin synthesis and complement-mediated hemolysis, the compound inhibited the release of lysosomal enzymes such as lysozyme and beta-glucuronidase in the passive Arthus reaction, suggesting the blockage of inflammatory mediator release for its mode of action." Get all the results and reference details, order at left...
5.	Asthma (Bronchial Asthma) 03/01/1989 - "KP-136 (1 mg/kg, i.v.) was also effective on allergic asthma of guinea pigs, although DSCG was ineffective even at a high dose of 50 mg/kg (i.v.)" 03/01/1989 - "KP-136 (0.125-1 mg/kg i.v., 0.5-2 mg/kg p.o.) produced a dose-dependent inhibition to allergic asthma of rats and was more potent than DSCG (1-5 mg/kg i.v.)" 03/01/1989 - "The pharmacological properties of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one, KP-136 were compared with those of an antiallergic medicament, disodium cromoglycate (DSCG) in experimental asthma models" 03/01/1989 - "Effect of 8-hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-one [KP-136] on experimental asthma: a comparison with disodium cromoglycate." 03/01/1989 - "In rats, both KP-136 and DSCG significantly blocked the reduction of histamine content of the trachea after allergic asthma and inhibited the antigen-induced histamine release from lung fragments (KP-136 0.5 micrograms/ml, DSCG 50 micrograms/ml) and peritoneal exudate cells (KP-136 0.1 micrograms/ml, DSCG 10 micrograms/ml)" Get all the results and reference details, order at left...
7 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	KP 136
2.	Muramidase (Lysozyme)
3.	Immunoglobulin E (IgE)
4.	Histamine (Histamine Dihydrochloride)
5.	Glucuronidase
6.	Enzymes
7.	Cromolyn Sodium (Cromoglicic Acid)
8.	p-Methoxy-N-methylphenethylamine
9.	Complement System Proteins (Complement)
10.	Carrageenan
11 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>